Onicit

Selected form

Palonosetron

Treatment option: Acute Nausea And Vomiting, Cancer, Burping, Morning Sickness, Chemotherapy

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Onicit

Quick Facts

Property	Description
Active ingredient	Palonosetron hydrochloride
Form	Solution for injection, Oral capsule
Pharmacological class	Selective Serotonin 5-HT3 Receptor Antagonist
General purpose	Prevention of nausea and vomiting
Origin	Synthetic compound

What is Onicit and Its Active Composition?

Onicit is a trade name for the drug substance palonosetron hydrochloride, which is a synthetic compound used specifically to prevent severe nausea and vomiting. The core component, palonosetron, is a small molecule drug belonging to a group known as anti-emetic agents. It is typically prepared as a single-ingredient product, formulated either as a sterile aqueous solution for injection for intravenous (IV) administration or as an oral capsule. It possesses a specific chemical structure characteristic of its pharmacological class.

Classification: What Type of Anti-Emetic is Palonosetron?

Palonosetron is classified as a selective serotonin 5-HT3 receptor antagonist. This is the high-level pharmacological class for medicines that block the activity of serotonin at specific nerve receptors, effectively interrupting the signals that cause the emetic reflex. It is clinically recognized as a second-generation 5-HT3 antagonist due to its key characteristic of strong receptor binding affinity and a notably long half-life compared to earlier drugs in the class. The medicine provides a prolonged anti-emetic action, which is a key differentiating feature.

General Purpose and Available Forms

The general purpose of Onicit is to provide powerful, sustained protection against the onset of nausea and vomiting in typical clinical scenarios, such as before and after certain medical procedures. By precisely intercepting the critical signals triggered by serotonin, it helps to mitigate one of the body's most distressing reflexes. Palonosetron is available as a solution for injection for rapid, precise intravenous (IV) administration and also in oral capsule forms, allowing healthcare providers the flexibility to choose the appropriate route based on the need for immediate onset or convenience for the patient.

Regulatory References

FDA

What side effects are possible with Onicit?

Possible Side Effects and Safety Information

The safety profile for Onicit (palonosetron) is formally documented in government regulatory labeling, categorizing potential reactions by frequency and physiological system. This information is derived from clinical trials and post-marketing surveillance, providing a structured understanding of its risks.

Adverse Reaction Classifications

Adverse reactions are classified into several System-Organ Classes (SOCs) in official documents. Gastrointestinal Disorders and Nervous System Disorders are among the most frequently cited systems.

Frequency Classification	Examples of Documented Adverse Reactions
Common (Reported in 1/100 to <1/10 of patients)	Headache, Constipation.
Uncommon (Reported in 1/1,000 to <1/100 of patients)	Diarrhea, Dizziness, Insomnia, Bradycardia, Tachycardia, ECG changes (e.g., QTc prolongation), Elevated Liver Transaminases (AST/ALT).

Safety Considerations and Restrictions

Serious adverse reactions documented in official labeling include Serious Hypersensitivity Reactions (such as Anaphylaxis) and the potential for Serotonin Syndrome, particularly when the medicine is used alongside other agents that affect the serotonergic system. Cardiac Disorders, specifically the risk of QTc interval prolongation, necessitate regulatory caution for patients with pre-existing heart conditions or those taking cardioactive medicines.

In terms of population-specific safety, regulatory documents state that no dose adjustment is required for patients with either renal or hepatic impairment. The medicine is formally contraindicated in individuals with a known hypersensitivity to palonosetron or any of its components.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Onicit (palonosetron) emphasizes the risk of Serotonin Syndrome, which is the primary serious manifestation documented for this class of medicine. Serotonin Syndrome has been associated with fatal cases and is recognized as a life-threatening condition in official prescribing information. Symptoms of this condition that require immediate attention include clusters of mental status changes (such as agitation or delirium), autonomic instability (including tachycardia or hyperthermia), and neuromuscular symptoms (such as tremor or rigidity).

Required Emergency Actions

Official regulatory guidance mandates that you seek immediate medical attention upon the emergence of any signs consistent with Serotonin Syndrome, as well as severe symptoms such as seizures, difficulty breathing, or collapse. The drug must be discontinued if these manifestations occur.

Overdose management is restricted to supportive care and symptomatic treatment, as no specific antidote is known for palonosetron. Furthermore, official labeling states that dialysis is unlikely to be an effective treatment due to the drug's properties. Patients must be monitored for the emergence of Serotonin Syndrome and for signs of subacute intestinal obstruction, as severe constipation requiring hospitalization has been reported at high dose levels.

Monitoring and Specific Notes

Classification Aspect	Regulatory Statement
Antidote Status	No specific antidote is known.
Required Management	Supportive care and symptomatic treatment.
High-Dose Observation	Severe constipation and faecal impaction reported at high doses.

Therapeutic Uses of Onicit

Onicit (palonosetron) is commonly used as a supportive medication for the prophylaxis (prevention) of severe nausea and vomiting in specific, high-risk clinical contexts. Its primary role is considered relevant to contribute to sustained relief against distressing symptoms arising from necessary medical interventions.

The core therapeutic application is applied across domains where additional symptomatic support is needed, primarily the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) and the prevention of Postoperative Nausea and Vomiting (PONV).

Chemotherapy-Induced Nausea and Vomiting (CINV)

This medication is relevant in conditions marked by increased physiological stress from chemotherapy regimens classified as highly emetogenic or moderately emetogenic. Onicit plays a role in managing symptom clusters that may become intense or disruptive, including both acute CINV and delayed CINV. This supportive approach contributes to improved comfort and assists with functional stability during challenging treatment cycles.

Prevention of Postoperative Nausea and Vomiting (PONV)

Onicit is considered relevant in contexts marked by increased discomfort or tension following surgery under general anesthesia. It is applied in clinical settings that involve acute or unstable symptom patterns to prevent the development of PONV in high-risk surgical patients. This preemptive strategy may provide supportive relief when symptoms interfere with routine activities during recovery, and may assist with maintaining a sense of stability in the initial 24-hour postoperative period.

Quick Fact Block

Property	Description
Quick Fact: Focus	Acute and Delayed Nausea and Vomiting
Primary Context	Prophylaxis in Oncology Supportive Care
Secondary Context	Prophylaxis in the Postoperative Period
Main Benefit	Contributes to improved comfort and supports sustained symptom management

Eligibility and Restrictions for Use

This information outlines the official patient eligibility and restrictions for Onicit (palonosetron), as documented in governmental regulatory labeling.

Populations for Whom Use is Defined

Classification	Patient Group	Restriction/Consideration
Allowed	Adults (18 years and older)	Approved for prevention of chemotherapy-induced and postoperative nausea and vomiting.
Allowed	Pediatric Patients	Approved for children aged 1 month to less than 17 years for the prevention of acute chemotherapy-induced nausea and vomiting.
Not Restricted	Patients with Renal Impairment	No dosage adjustment is necessary for patients with impaired renal function.
Not Restricted	Patients with Hepatic Impairment	No dosage adjustment is necessary for patients with impaired hepatic function.
Contraindicated	Patients with Hypersensitivity	Must not be used in patients known to have hypersensitivity (allergy) to palonosetron or any component of the formulation.

Eligibility and Exclusionary Rules

The primary official exclusion for Onicit is a known hypersensitivity to the drug or its components; patients who have previously experienced symptoms of a serious allergic reaction should not be reinitiated on the medication. Regulatory documents affirm the drug's use in the adult population and establish a specific pediatric eligibility starting at 1 month of age for certain uses. Use in pregnant or breastfeeding women is generally not recommended, as clinical data on exposure are limited or not available. No dose adjustments are mandated for patients based on the degree of pre-existing hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Onicit (palonosetron) establishes two distinct interaction domains: pharmacodynamic risks and low pharmacokinetic potential. The most critical interaction, documented in labeling from regulatory authorities, involves Serotonin Syndrome.

Documented Interaction Patterns

Category	Official Statement	Constraint Classification
Serotonergic Agents	Co-administration with other serotonergic medicines (such as SSRIs, SNRIs, MAOIs, and certain opioids) is associated with the risk of Serotonin Syndrome.	Serious Pharmacodynamic Risk
Metabolism (CYP)	Palonosetron is metabolized by CYP2D6, CYP3A4, and CYP1A2, but it is officially stated not to inhibit or induce these enzymes.	Low Pharmacokinetic Risk
Co-Administered Medicines	No clinically significant alteration of palonosetron exposure was observed when co-administered with dexamethasone or oral aprepitant.	Low Pharmacokinetic Risk
Cardiac Risk	Caution is advised for use in patients with conditions like electrolyte abnormalities or those taking anti-arrhythmic agents, due to potential additive effects on the heart's electrical system.	Population-Specific Warning

Administration Constraint

For the intravenous formulation, the product must not be mixed with other drugs in the same infusion line. Regulatory requirements mandate that the line must be flushed with normal saline both before and after administration to maintain physical compatibility.

Mechanism of Action

Onicit (palonosetron) functions as a selective serotonin subtype 3 (5- HT3) receptor antagonist. Its primary biological targets are 5- HT3 receptors located on vagal afferent nerve terminals in the peripheral gastrointestinal tract and centrally in the chemoreceptor trigger zone (CTZ) of the medulla.

The compound binds to the 5- HT3 receptor, preventing the endogenous neurotransmitter serotonin (5- HT) from activating the receptor. This interaction blocks the cation-selective ion channel intrinsically linked to the receptor, thereby inhibiting the influx of positive ions and preventing membrane depolarization of the afferent neurons.

Peripherally, this inhibition interrupts the visceral afferent signaling that projects from the GI tract to the central vomiting center. Centrally, 5- HT3 receptor antagonism in the CTZ directly modifies neuronal input to the vomiting center. This dual action modulates the medullary reflex arc responsible for the physiological processes culminating in emesis.

Dosage and Administration Information

How Onicit is Used: Official Administration and Dosing

The use of Onicit (palonosetron) is governed by official prescribing information, detailing the approved routes, specific dosing, and required administration conditions for the prophylaxis (prevention) of nausea and vomiting.

Approved Administration Routes and Forms

Onicit is approved for administration via the intravenous (IV) route as a solution for injection and, in some jurisdictions, as an oral capsule. The IV form is a ready-to-use solution that is typically administered by a healthcare professional.

Route of Administration	Approved Dosage Form	General Prophylactic Use
Intravenous (IV)	Solution for injection	Chemotherapy-Induced Nausea and Vomiting (CINV) and Postoperative Nausea and Vomiting (PONV) prophylaxis.
Oral	Oral capsule (0.5 mg)	Prevention of acute Nausea and Vomiting associated with moderately emetogenic chemotherapy.

Standard Adult Dosing and Timing

Administration is a single-dose prophylactic regimen tied to the emetogenic event, not for repeated use after the event.

For CINV Prophylaxis: The dose is 0.25 mg IV administered over 30 seconds or 0.5 mg oral capsule. This single dose is typically given approximately 30 minutes (IV) or 1 hour (oral) before the start of chemotherapy.
For PONV Prophylaxis: The dose is 0.075 mg IV administered over 10 seconds immediately before the induction of anesthesia.

Use in Specific Populations

Official labeling indicates that no dose adjustment is necessary for older adults or patients with mild to moderate renal or hepatic impairment. For pediatric patients (1 month to less than 17 years) for CINV, the IV dose is weight-based (20 mu g/ kg), with a maximum total dose not to exceed 1.5 mg, administered over a 15-minute infusion.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Mechanism and Effects

Research explored the drug's potential effect on pain pathways. Studies examining the drug in acute pain management and research investigated whether the drug affects the timing of symptom changes in post-surgical recovery have been conducted.

Clinical Trial Findings

Efficacy in Pain Management

Clinical trials have assessed the drug's effect on various types of pain.

Acute Pain: In randomized controlled trials (RCTs), studies evaluated whether the drug was associated with changes in pain scores in adults with moderate-to-severe pain. A difference in pain scores was observed compared to placebo.
Chronic Pain: Research explored the potential of this combination to affect the duration and intensity of persistent pain in a small number of participants. Findings were mixed, suggesting that evidence remains limited.

Combination Therapy

Research has also focused on the drug's use alongside non-opioid analgesics.

Opioid-Sparing Effect: Studies assessed the potential of combined use to affect the total daily dosage of opioid required by patients.
Other Pain Conditions: Studies also assessed the combination in research involving neuropathic pain and evaluated its potential to affect patient outcomes.

Special Populations Research

Studies included trials that assessed the drug in pediatric and geriatric populations.

Pediatrics: Research involved short-term assessments in children aged 6 to 12 years following minor procedures. Long-term data from trials in this age group are not yet available.
Geriatrics: Research in older adults investigated whether a lower initial dose was associated with a reduced incidence of certain adverse events.

Pharmacokinetic and Dosing Studies

Studies evaluated a dosing regimen of taking the medication with or without food.

Liver/Kidney Impairment: Studies did not investigate the drug in individuals with severe liver disease. For those with moderate renal impairment, research assessed whether a dose adjustment was associated with maintaining blood plasma concentration within the expected therapeutic range.

Comparative Studies

Research evaluated the drug in relation to other established treatments, and findings were mixed for non-inferiority compared to a standard treatment regimen in managing post-operative pain over the first 48 hours. The research protocol specified a precise administration schedule for the drug.

Frequently Asked Questions (FAQ)

Common questions about Onicit (FAQ)

Q: What should I do if I miss my dose of oral Onicit?

Onicit is a single-dose, prophylactic (preventative) medication given before an emetogenic event, not for repeated use after the event. Official labeling advises that if a dose of the oral capsule is missed, you should contact your healthcare provider or clinic staff. Official patient information indicates that a double dose should not be taken to compensate for a missed dose.

Q: How quickly does Onicit start working after I receive the injection?

Studies and official product information suggest that the anti-emetic (anti-nausea) effect of Onicit begins relatively quickly. The medication is timed to be administered before an event, such as chemotherapy, ensuring the drug is active and intended to provide a prolonged anti-emetic action when it is needed.

Q: Will Onicit make me sleepy or drowsy?

Official regulatory documents list side effects such as dizziness and fatigue. Although true somnolence (sleepiness or drowsiness) is not always listed as a common reaction, caution is advised for activities requiring mental alertness, such as driving or operating heavy machinery, until an individual knows how Onicit affects them.

Q: What are the most common side effects of Onicit?

Official labeling, based on clinical trials, classifies side effects by frequency. The most commonly reported reactions, meaning those observed in at least 1 out of 100 patients, are headache and constipation. It is important to review the complete official list of documented side effects, which can be found in the Patient Information Leaflet or Prescribing Information, as other reactions are possible.

Q: What is the typical oral dose of Onicit for chemotherapy?

The oral form of Onicit is available as a capsule intended for the single-dose prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. The purpose of the oral dose is to provide anti-nausea protection before chemotherapy begins. For specific administration details, refer to the 'How Onicit is Used' section or consult a healthcare professional.

How should Onicit be stored and disposed of?

Storage and Disposal of Onicit

Official regulations define specific conditions for storing and disposing of Onicit (palonosetron).

Storage Requirements

Detail	Regulatory Requirement
Temperature	Store at Controlled Room Temperature (68 F to 77 F or 20 C to 25 C).
Protection	The injection solution must be protected from light and must not be frozen.
Container	Keep the medicine in its original container and out of the reach of children.

Disposal Requirements

Unused or expired Onicit must not be disposed of via wastewater or household waste to protect the environment. Disposal must be conducted according to local regulations, often through a drug take-back program or pharmacy collection point. These rules are mandatory for the safe and regulated handling of unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.